Investigational therapies under clinical investigation

There are several new therapies under investigation for use in HCM. Below is a list of several medications at different stages of discovery, trial, or submission to the FDA (Food and Drug Administration - USA)

CK-274: This agent is in the same class as Mavacamten, with slight differences in the action.   Clinical trials are ongoing. Sponsor: Cytokinetics

IMB-101 Indication: HCM: Phase 2 study in non-obstructive HCM.  For non-obstructive HCM patients with preserved systolic function (ejection fraction (EF) ≥50%) who develop symptoms refractory to drug therapy, a heart transplant remains the only definitive long-term management option. Sponsor: Imbria Pharmaceuticals

TN-201: This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic MYBPC3 mutation-associated nonobstructive hypertrophic cardiomyopathy (nHCM). Sponsor: Tenaya Therapeutics

HCMA 7/2023